RxDoctor Payments Data

Navita Gupta, MD

Internal Medicine · Metairie, LANPI 1982961579

Payments from drug & device makers

$1,579in general payments, 2019–2025

Across 97 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$414
  • Pfizer$255
  • Novo Nordisk$153
  • GSK$142
  • AbbVie$138
  • Exact Sciences$74
  • plus $403 from 17 others

What the payments were for

  • Food & beverage$1,579100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,579 in reported general payments places this provider in the 70th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$96,215
Medicare patients
329
Services billed
1,066

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide150$163,165
MounjaroTirzepatide55$64,110
TrulicityDulaglutide25$46,536
JanuviaSitagliptin Phosphate54$45,384
JardianceEmpagliflozin36$35,848
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$28,679
LinzessLinaclotide25$18,427
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$17,971
EliquisApixaban20$17,942
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$17,600
FarxigaDapagliflozin Propanediol17$14,440
MyrbetriqMirabegron21$12,565
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$9,260
EntrestoSacubitril/Valsartan12$8,547
Sucralfate15$6,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$153$163,165150 claims
Lilly USA, LLCMounjaro, Trulicity$414$110,64680 claims
AstraZenecaBreztri Aerosphere, Farxiga$45$32,04138 claims
GSKTrelegy Ellipta$142$28,67933 claims
PfizerEliquis, Premarin$255$20,10331 claims
AbbVieLinzess$138$18,42725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →